Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B

Creative Commons License

Atay K., Hatemi I., Canbakan B., Koroglu E., Durcan E., Yurttas B., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.27, sa.3, ss.279-283, 2016 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5152/tjg.2016.16085
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.279-283
  • Anahtar Kelimeler: Antiviral agents, Hepatitis B, lamivudine, LAMIVUDINE TREATMENT, COST-EFFECTIVENESS, VIRUS, PREVALENCE, EFFICACY
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low adverse effect profile and cost. It is important to know which patients might benefit from lamivudine as the first-line treatment. We aimed to assess the success rates of lamivudine, entecavir, and tenofovir, as well as the resistance rates, frequencies of HBsAg clearance, and risk factors for lamivudine resistance.